New research indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional diet and exercise regimens.
Findings released in a prominent health publication points out that while overweight individuals often shed a large proportion of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals using these treatments need to be cognizant of the danger of fast rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass within about 18 months.
Analyzing Approaches
The analysis, which looked at dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting typically have a more gradual creep back—around 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Doctors believe the mechanism of the drugs is key to understanding the accelerated rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' means hunger is unsuppressed, making binge eating much more probable."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the treatment should be considered ongoing.
This view is echoed by pharmaceutical companies, who say that the findings "highlight the chronic character of obesity," comparing it to managing diseases like diabetes.
User Testimonies
Individuals who have discontinued the jabs report a powerful resurgence of cravings.
"It felt as if a trigger flipping and you become extremely hungry," recalled an individual.
This difficulty is worsened if users have not adopted permanent lifestyle or habit changes during therapy.
Growing Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Use is greater among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural support.
